Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil in HFpEF and PH
NCT01726049Phase 3Completed
- Sponsor
- University Medical Center Groningen
- Start
- Oct 2011
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ASP-001 in heart failure with preserved ejection fraction (HFpEF) and pulmonary hypertension (PH) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Mean Pulmonary Artery Pressure Measured by Right Heart Catheterization at 12 weeks. Started Oct 2011; status: completed.
02
Drugs
ASP-001
03
Conditions
heart failure with preserved ejection fraction (HFpEF)pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT01726049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01726049.